131 related articles for article (PubMed ID: 36272336)
1. Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
Hegmann L; Sturm S; Niegisch G; Windolf J; Suschek CV
J Photochem Photobiol B; 2022 Nov; 236():112582. PubMed ID: 36272336
[TBL] [Abstract][Full Text] [Related]
2. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
[TBL] [Abstract][Full Text] [Related]
5. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
[TBL] [Abstract][Full Text] [Related]
6. Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
Sturm S; Niegisch G; Windolf J; Suschek CV
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732087
[TBL] [Abstract][Full Text] [Related]
7. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
9. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Yen WC; Schmittgen T; Au JL
Pharm Res; 1996 Dec; 13(12):1887-91. PubMed ID: 8987090
[TBL] [Abstract][Full Text] [Related]
10. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
11. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors.
Gontero P; Sargent JM; Hopster DJ; Lewandowic GM; Taylor CG; Elgie AW; Williamson CJ; Sriprasad SI; Muir GH
Anticancer Res; 2002; 22(6C):4073-80. PubMed ID: 12553035
[TBL] [Abstract][Full Text] [Related]
13. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Faraj K; Chang YH; Rose KM; Habermann EB; Etzioni DA; Blodgett G; Castle EP; Humphreys MR; Tyson Ii MD
Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
[TBL] [Abstract][Full Text] [Related]
14. [Blood and tissue levels of mitomycin C after intravesical instillation].
Flüchter SH; Hlobil H; Harzmann R; Rothe KF; Bichler KH
Urol Int; 1983; 38(6):321-8. PubMed ID: 6419427
[TBL] [Abstract][Full Text] [Related]
15. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
O'Brien T; Ray E; Singh R; Coker B; Beard R;
Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
[TBL] [Abstract][Full Text] [Related]
16. 7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Rohde D; Raffenberg G; Kaviani S; Wolff J; Jakse G
Urol Res; 1998; 26(4):243-7. PubMed ID: 9759997
[TBL] [Abstract][Full Text] [Related]
17. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
[TBL] [Abstract][Full Text] [Related]
18. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
19. Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Verma A; Degrado J; Hittelman AB; Wheeler MA; Kaimakliotis HZ; Weiss RM
BJU Int; 2011 Apr; 107(7):1154-61. PubMed ID: 20735383
[TBL] [Abstract][Full Text] [Related]
20. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
